Therapeutic plasma exchange (TPE) has dramatically improved the prognosis of acquired
thrombotic thrombocytopenic purpura (TTP), and TPE and corticosteroids are the mainstays …

Background Rituximab has been documented in the treatment of acute (≤ 3 days from
admission), relapsed/refractory thrombotic thrombocytopenic purpura (TTP) and given as …

In acquired thrombotic thrombocytopenic purpura (TTP), the persistence of severe
ADAMTS13 deficiency (< 10%) during remission is associated with more relapse …

Despite a significant improvement of thrombotic thrombocytopenic purpura (TTP) prognosis
since the use of plasma exchange, morbidity and mortality remained significant because of …

Patients with immune-mediated thrombotic thrombocytopenic purpura (iTTP) often
experience life-threatening relapses of the disease, and rituximab (RTX) can be used to …

The majority of the patients affected by acquired thrombotic thrombocytopenic purpura (TTP)
develop autoantibodies directed towards ADAMTS13 that interfere with its von Willebrand …

Modern therapy for acute TTP has resulted in a dramatic improvement in outcomes, with the
combination of plasma exchange, immunosuppression, and caplacizumab being associated …

Rituximab has been added to therapeutic plasma exchange (TPE) in the last 10 years for
refractory thrombotic thrombocytopenic purpura (TTP). We performed a retrospective single …

Objective Idiopathic thrombotic thrombocytopenic purpura (TTP) is a life-threatening
disorder mediated by autoantibodies directed against ADAMTS13. This provides a rationale …

BACKGROUND Appropriate management to prevent relapses of acquired, autoimmune
thrombotic thrombocytopenic purpura (TTP) is not clear. Rituximab (375 mg/m2/week× 4) is …